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Background Definition of objective criteria to conclude the severity of MS
is still important.
Aims (1) to evaluate correlation between the mean transmitral gradient
(MTG) and severity of MS in patients with a severe or very severe MS (2) To
analyze the different parameters which determine the mean transmitral gradient.
Methods We conducted a prospective study including fifty patients
admitted for severe or very severe MS, over a period of one year.
We first studied the correlation between mitral valve area and MTG. Then
we separately analyzed two groups of patients: those with a MTG <10mmHg
(group 1) and those with a MTG>10mmHg (group2). We performed for each
group an univariate correlation between MTG and dyspnea, heart rate, cardiac
decompensation, regularity of rhythm, function of right ventricle and systolic
pulmonary artery pressure (SPAP).
Results 64% of our patients had a severe MS and 36% had a very severe
MS. 52% had a MTG <10mmHg and 48% had a mean gradient>10mmHg;
suggesting lack of correlation between the severity of MS and MTG (Pearson
coefficient R: –0.137).
Regarding dyspnea, 80% of patients in group 1 had a dyspnea stage II of
NYHA and 70% of patients in group 2 had a dyspnea stage III (41%) or IV
(29%).
The analytical study of heart rate (HR) and the presence of cardiac decom-
pensation compared with MTG showed a significant correlation. Among the
patients in group 1, 96% had a HR between 60 and 100 bpm and no patient
was in cardiac decompensation. In group 2, 54% (13 patients) had a HR >100
bpm and 7 of them (53%) were in left heart failure. The study of SPAP in the
two groups found a statistically significant correlation between the SPAP and
MTG.
Conclusion Mean transmitral gradient is a good indicator of the tolerance
of mitral stenosis, but it reflects poorly severity because it depends on several
hemodynamic parameters.
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Background Systemic Sclerosis (SSc) represents the main connective
tissue disease associated with PAH.
This PAH is the leading cause of death, which only screening and early
diagnosis can improve prognosis. 
Echocardiographic screening represents so fare the ideal tool for the early
detection of this PAH.
Aim Evaluate the prevalence of PAH in Scleroderma Algerian Population
and its distribution according to clinical forms of the disease.
Methods We conducted a cross-sectional descriptive study from Dec. 2010
to Dec. 2013. 
202 patients (177 women and 25 men) with SSc were enrolled.
We used a screening algorithm based on the maximum velocity of tricuspid
regurgitation (VIT) and dyspnea. This defined patients at high risk (VIT >3 m/s or
VIT between 2.8 and  3 m/s with dyspnea unexplained by another cause). Who
were submitted to right heart catheterization (RHC) to confirm PH.
Results Pulmonary hypertension suspected on echocardiography was
confirmed by RHC in 68.2% of cases.It was a pre-capillary PH.VIT ≥3,48 m/s
strongly suggests PH. 
The prevalence of PAH was 6%. 
The mean delay of it occurrence was 7.08 years after first diagnosis of SSc.
PAH occurred in the first five years in 58.3% of cases and after five years in
41.6% of cases.
It concerns the diffuse cutaneous forms in 33.3% or 0.5% of diffuse forms
of our patient’s population and limited in 58.3% of cases or 0.58% limited
cutaneous forms in our patients population. A frequency of 0,08% was found
in limited form. 
Dyspnea is the primary symptom found, 67% of patients were in class III
and IV at diagnosis.
Conclusion Prevalence of PAH in scleroderma was 6%, our findings are
similar to the results reported in the literature: 
5-12%, through echocardiographic screening and catheterize confirmation.
This strengthens the fact that an echocardiogram should be performed at
the time of SSc diagnostic and this regardless of the clinical form of SSc.
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Introduction Percutaneous mitral commissurotomy (PMC) is the gold stan-
dard technique for the management of severe rhumatismal mitral stenosis
(MS). We investigated the utility of BNP, NT pro-BNP, MR pro-ANP, CD146
and sST2 in evaluating the success of the PMC procedure.
Methods All 5 biomarkers were measured one day before and one day after
the procedure in 43 patients presenting with severe MS (defined as mitral
valve area (VA) by planimetry <0.2cm2) and submitted to PMC in 2 large uni-
versity hospitals in France (CHU Bichat, Paris; CHU Jean Minjoz, Besancon).
Patients were classified as procedural success (VA >1.5cm2 or increase in VA
>0.5cm2) or failure (VA <1.5cm2 or increase in VA <0.5cm2) by echocardiog-
raphy. The absolute decrease in each biomarker between before and after the
procedure was compared for each patient using the paired Student t test. 
Results In total, 43 patients were included (80% women, average
63.7 years), of whom 30 (70%) were judged to have a successful procedure by
echocardiography; 11 (25%) were classed as procedural failure, and 2 (5%)
had a major complication (1 mitral insufficiency requiring surgery, 1 tam-
ponade). Among the 30 patients with procedural success, there was a signifi-
cant decrease in MR pro-ANP (–40±74, p=0.02) and CD146 (–43±105,
p=0.03). There was no significant decrease in patients classed as procedural
failures. There was no significant decrease in BNP, NT pro-BNP or sST2 in
patients with either successful or failed procedure. 
Conclusion There is a significant decrease in MR pro-ANP and CD146
after successful PMC. The difference is more pronounced in younger patients
and in those in sinus rhythm. These two biomarkers could be of use in evalu-
ating the immediate success of PMC. 
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Background Paravalvular aortic regurgitation (PAR) after TAVR has been
associated with increased mortality. The Sapien 3 device (Edwards Life-
sciences) is different than the prior devices released by the same manufacturer
